Nanobiotix is trading at $28.74, down 8.38%, with no clear company-specific announcement identified to explain the November 2 move. - The latest prominent company update was October 24 clinical data for its melanoma study. - A November 2 market report described the decline as a pullback after a sharp rebound and noted the Paris market was higher, but identified no specific catalyst. - The supplied major indices were rising, but available evidence does not establish a broader-market explanation.